Villodre et al demonstrated that NDRG1 is an independent factor of worse prognosis in pre‐treated inflammatory BC patients [12] and reported elevated NDRG1 expression to be linked with poorer clinical outcomes in the aggressive phenotypes of BC (HER2+, ER− or TNBC). This evidence concerns the gene ERBB2 and breast cancer.